Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC lessened its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 25.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,500 shares of the company’s stock after selling 4,500 shares during the quarter. Gabelli Funds LLC’s holdings in Lifecore Biomedical were worth $100,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. ARS Investment Partners LLC acquired a new position in Lifecore Biomedical during the 4th quarter valued at approximately $74,000. Prudential Financial Inc. purchased a new stake in shares of Lifecore Biomedical during the fourth quarter valued at $95,000. Wells Fargo & Company MN raised its stake in Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company’s stock worth $99,000 after acquiring an additional 3,012 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Lifecore Biomedical during the 3rd quarter worth about $119,000. Finally, Barclays PLC grew its stake in Lifecore Biomedical by 301.7% during the 3rd quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after purchasing an additional 22,489 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Stock Performance

LFCR opened at $6.41 on Monday. The company has a market cap of $237.33 million, a price-to-earnings ratio of -11.45 and a beta of 0.80. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99. The firm’s fifty day simple moving average is $6.17 and its two-hundred day simple moving average is $6.33. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $35.15 million during the quarter, compared to analysts’ expectations of $33.23 million. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Equities analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.